PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?

Chemotherapy Clear Cell Ovarian Carcinoma Endometriosis Histological origin Lymphadenectomy

Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
18 Mar 2024
Historique:
received: 18 11 2023
revised: 08 02 2024
accepted: 17 03 2024
medline: 23 3 2024
pubmed: 23 3 2024
entrez: 22 3 2024
Statut: aheadofprint

Résumé

Our primary aim in this study is to define the clinical characteristics of patients with clear-cell ovarian carcinoma and evaluate the prognostic factors affecting survival. Records of 85 patients, operated between 2000 and 2018, for an adnexal mass and whose final pathology reported clear cell ovarian carcinoma were reviewed. The study considered demographic data, clinical characteristics of the patients, as well as pure and mixed-type clear cell histology. The patients' follow-up time, disease-free and overall survival recorded. The primary outcomes were disease-free survival (DFS) and overall survival (OS). The median age of the patients at diagnosis was 52. In 64.7 % of the cases, clear cell histology was pure, while the others (35.3 %) were mixed. Patients with ovarian endometriosis constituted 27.1 % of the whole population. The median OS for the entire population was 92 months (95 %CI:72-124). On univariate and multivariate analyses, advanced age was found to have a significant independent impact on OS and DFS (p < 0.05) and, was associated with a worse prognosis. Also, the multivariate analyses showed that the presence of endometriosis has a significant independent impact on OS (p < 0.05). When examining the relationship between the histological origin (mixed vs. pure) and 5-year survival, the mixed type showed longer OS and DFS rates (76.8 % vs. 69.8 %, 61.5 % vs. 53.8 %), the difference was not statistically significant (p > 0.05). This retrospective study showed that although mixed type histological origin was associated with higher OS and DFS rates compared to pure type in patients with CCOC, the difference was not statistically significant. Advanced age and the presence of endometriosis was found to have a significant independent effect on OS and DFS and was associated with a worse prognosis. Overall, this study provides useful insights into the clinical characteristics of patients with CCOC and identifies important prognostic factors affecting survival.

Identifiants

pubmed: 38518487
pii: S0301-2115(24)00141-6
doi: 10.1016/j.ejogrb.2024.03.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

321-326

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Duygu Güzel (D)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Manisa City Hospital, Manisa, Turkiye.

Coşan Terek (C)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Ege University, İzmir, Turkiye.

Ayşegül Besler (A)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Tepecik Education and Research Hospital, İzmir, Turkiye.

Gürdeniz Serin (G)

Department of Pathology, Ege University, İzmir, Turkiye.

Züleyha Önal (Z)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Ege University, İzmir, Turkiye.

Levent Akman (L)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Ege University, İzmir, Turkiye.

Erdem Göker (E)

Division of Medical Oncology, Department of Internal Medicine, Ege University, İzmir, Turkiye.

Ulus Ali Şanli (U)

Division of Medical Oncology, Department of Internal Medicine, Ege University, İzmir, Turkiye.

Osman Zekioğlu (O)

Department of Pathology, Ege University, İzmir, Turkiye.

Necmettin Özdemir (N)

Department of Pathology, Ege University, İzmir, Turkiye.

Aydın Özsaran (A)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Ege University, İzmir, Turkiye.

Nuri Yildirim (N)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Ege University, İzmir, Turkiye. Electronic address: nuri-yildirim@hotmail.com.

Classifications MeSH